FDA approves Zytiga for late-stage prostate cancer The U.S. Food
FDA approves Zytiga for late-stage prostate cancer
The U.S. Food and Drug Administration today approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).